ANACOR TO PRESENT AT NEEDHAM LIFE SCIENCES CONFERENCE

Palo Alto, Calif. - June 2, 2009 - Anacor Pharmaceuticals announced today that David Perry, Chief Executive Officer, will provide a company overview at the 8th Annual Needham Life Sciences Conference at 1:30 p.m. ET on Thursday, June 11, 2009 in New York, NY.

About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antiviral and antibacterial therapeutics under a research and development agreement with GlaxoSmithKline. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough Corporation under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. For more information www.anacor.com.

Contact:
Anne Bowdidge
Investor Relations
650-543-7575